Search

everythinglearnresearchcommunity

for

Search:↓

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.

Finasteride breakdown products found in bile and urine, helps understand drug safety and effectiveness.

Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.

Improved tablets lead to faster, better drug absorption for hair loss treatment.

New hair follicle-targeting treatments show promise for hair disorders but need more research on safety and effectiveness.

Some psychoactive drugs can cause skin reactions, with carbamazepine having a higher risk, and stopping the drug and seeing a dermatologist is important.

Using hair follicles can improve skin drug delivery.

A machine learning model called CATNIP can predict new uses for existing drugs, like using antidepressants for Parkinson's disease and a thyroid cancer drug for diabetes.

Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Ingenol mebutate gel changes gene expression related to skin development and immune response in actinic keratosis.

Computational tools identified 29 drugs that could potentially target 19 genes involved in chemotherapy-induced hair loss, which could lead to more effective treatments.

Skin reactions are a common reason for emergency visits due to drug allergies, with some severe cases needing intensive care.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

Microemulsions could improve skin drug delivery but face challenges like complex creation and potential toxicity.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Recreational drug use can cause misdiagnosed conditions and drug interactions in HIV patients.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Most pediatric cancer patients at Muhimbili National Hospital in Tanzania experienced side effects from chemotherapy, with nausea, hair loss, and low white blood cell count being the most common.

Women with PCOS may have a higher risk of severe COVID-19 due to hormonal imbalances and vitamin D deficiency.

Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.

Biodegradable polymers can improve cannabinoid delivery but need more clinical trials.

Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Drug repurposing speeds up drug development, saves money, and has led to about a third of new drug approvals.